RESUMOObjetivo: comparar laboratorialmente a atividade antimicrobiana de amostras do óleoresina de copaíba (Copaifera sp.) natural e comercial sobre as bactérias Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 25922 e Staphylococcus aureus ATCC 25923. Método: Trata-se de um estudo transversal descritivo ao qual utilizou-se a técnica de cilindro em placa além da determinação da concentração inibitória mínima do óleo em ágar Mueller-Hinton. Para o controle positivo foi utilizado solução de Hidróxido de Sódio e para o controle negativo, solução fisiológica de Cloreto de Sódio. Resultados: o óleo de copaíba natural e comercial apresentou potencial de inibição do crescimento bacteriano satisfatório sobre as cepas Staphylococcus aureus ATCC 25923 e Escherichia coli ATCC 25922, sendo a bactéria Pseudomonas aeruginosa ATCC 9027 resistente ao óleo na concentração de 150µL da solução. A atividade antimicrobiana variou de acordo com os óleos e os patógenos estudados; nas concentrações de 100% até 3,1% houve inibição da cepa Escherichia coli ATCC 25922 e de 100% a 25% da cepa Staphylococcus aureus ATCC 25923, em ambos os óleos de copaíba. Conclusão: o óleo de

Background: COVID-19 is a rapidly transmissible pneumonia-like illness caused by SARS-CoV-2 that out broke in China in 2019 and is currently circulating worldwide. In the current context of the SARS-CoV-2 pandemic, complications are observed in clinical settings for the treatment of severe COVID-19 disease in nosocomial settings, due to cases of fungal co-infections. Objective: To carry out a review on fungal infections associated with respiratory infections caused by COVID-19 (Sars-Cov-2) and their aggravation. Methodology: The purpose of this study is to inform the reader about the characteristics of SARS-CoV-2 and the main fungal species that are affecting patients undergoing treatment for severe COVID-19, provoking discussion of the importance of the proposed topic, in relation to co-infections by different fungal microorganisms. Result: 80 scientific studies were selected, resulting from patients with COVID-19 and most commonly observed in patients with a history of comorbidities such as diabetes mellitus, hypertension, kidney disease, severe liver disease, oncological diseases, obesity and with severe COVID-19. These data do not represent the total number of records of the disease in the world, but cases reported by researchers in their series, showing the overlapping of fungal co-infection through the compromised immune status due to the use of therapeutic drugs, dysregulation of the microbiota, How to cite this paper: Mariscal, A.